Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + irinotecan + trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer
ACTRN12617001190392Phase 2Recruiting
- Sponsor
- Central Adelaide Local Health Network
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab, irinotecan and trifluridine + tipiracil in colorectal cancer (CRC) (4 arms), sponsored by Central Adelaide Local Health Network. Primary endpoints: Maximum tolerated dose and Progression-free survival. Started Jul 2018; status: recruiting.
02
Drugs
panitumumabirinotecantrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12617001190392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001190392.